VP, CMC & Manufacturing
Remote
$140,000–$165,000
Location: Flexible
Reports to: CEO
Employment Type: Consulting (20–30 hrs/week) transitioning to Full-Time
About LionBio
LionBio is developing the first intranasal GLP-1 receptor agonist powered by a proprietary nanoparticle delivery platform. Our mission is to transform how metabolic medicines are delivered, creating a more effective and patient-friendly alternative to existing therapies.
Starting with obesity and metabolic health, we are building a platform with the potential to expand across multiple therapeutic areas through innovative nose-to-brain drug delivery technology.
The Opportunity
We are seeking a Vice President of CMC & Manufacturing to build and lead LionBio's manufacturing strategy from the ground up. This role will own the development, scale-up, and supply chain infrastructure required to bring our nanoparticle platform from laboratory innovation to commercial reality.
The ideal candidate brings deep expertise in pharmaceutical manufacturing, drug delivery systems, and CMC strategy, with experience managing external manufacturing partners and preparing products for clinical development.
What You'll Do
Lead CDMO evaluation, selection, contracting, and ongoing manufacturing oversight
Drive nanoparticle formulation development, process optimization, and scale-up activities
Manage technology transfer from research-stage processes into scalable GMP manufacturing
Source and qualify peptide active pharmaceutical ingredients (APIs) and establish a resilient supply chain
Evaluate and select nasal delivery devices and oversee device qualification activities
Develop analytical methods and quality specifications for nanoparticle characterization
Build and manage manufacturing and distribution workflows supporting clinical and commercial programs
Author and contribute to CMC documentation supporting regulatory submissions
Oversee GMP manufacturing activities for clinical trial supply
Qualifications
Required
M.S. or Ph.D. in Chemical Engineering, Pharmaceutical Sciences, Materials Science, or a related discipline
10+ years of pharmaceutical CMC and manufacturing experience
Direct experience with nanoparticle, microsphere, or advanced drug delivery manufacturing
Experience managing peptide APIs, sourcing strategies, and supplier qualification
Background in nasal, inhaled, or drug-device combination products
Proven track record managing CDMOs, technology transfers, quality agreements, and manufacturing scale-up
Preferred
Leadership experience within nasal, inhaled, or advanced drug delivery companies
Experience with microfluidics-based nanoparticle manufacturing
Familiarity with compounding pharmacy and specialty pharmaceutical supply chains
Previous experience at seed-stage or early-stage biotechnology companies
Comfort operating in fast-moving, resource-constrained startup environments
Why Join LionBio
Build the manufacturing foundation for a first-in-class intranasal therapeutic platform
Own the entire CMC strategy from formulation through clinical supply
Work at the intersection of metabolic health, nanoparticle science, and advanced drug delivery
Partner directly with company leadership and world-class scientific advisors
Join at an early stage with meaningful ownership and influence over company strategy
Compensation
Consulting Phase
$200–$300 per hour
20–30 hours per week
Initial consulting engagement with pathway to full-time leadership role
Full-Time Compensation
Base Salary: $150,000–$250,000
Equity: 1.0–2.0% ownership (4-year vesting schedule with 1-year cliff)
Compensation is designed to provide significant long-term upside through meaningful equity participation alongside competitive early-stage biotech compensation.
First-Year Goals
Select and onboard manufacturing partners
Establish peptide API sourcing and supply agreements
Complete nasal device evaluation and selection
Initiate technology transfer and produce pilot manufacturing batches
Deliver material supporting preclinical development activities
Prepare manufacturing processes and supply for first-in-human clinical studies